Skip to main content
S&P 5007,541.40-0.51%DOW51,983.98+0.41%NASDAQ25,164.36-1.07%BTC$77,142.00-1.60%ETH$2,258.53-1.35%GOLD$3,958.40-0.28%OIL$96.61+0.16%
Smart Investors Daily
SID Premium
IM

NASDAQ · IMVT

Immunovant, Inc.

Healthcare · Biotechnology

$28.41

Down-$0.76 (-2.61%)

Updated Nov 3, 2026, 7:30 AM

SID Score

4.8/10

Composite research score

Smart Money

58/100

Neutral

Market cap
4.35B
P/E ratio
-9.28
Dividend yield
0.00%
52-week range
$22.79 – $45.42
Volume
1.27M
Avg. volume
1.69M

Price performance · IMVT

IMVT price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 2, 2026

IMVT closed at $28.41 after 21 trading sessions, down 14.56% for the selected period.

Last close
$28.41
Period change
-14.56%
Period low
$26.73
Period high
$33.25
Daily close
View OHLC price history
IMVT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 2, 2026$29.32$29.64$28.38$28.411.27M
Oct 30, 2026$29.49$29.78$28.755$29.171.17M
Oct 29, 2026$29.56$30.15$29.33$29.641.4M
Oct 28, 2026$28.50$29.47$28.415$29.421.24M
Oct 27, 2026$28.25$28.96$28.005$28.881.06M
Oct 26, 2026$28.46$28.50$27.625$28.171.2M
Oct 23, 2026$28.93$28.93$28.14$28.41641.44K
Oct 22, 2026$28.09$29.12$27.98$29.101.16M
Oct 21, 2026$28.97$29.18$28.05$28.381.49M
Oct 20, 2026$27.76$29.135$27.62$28.591.45M
Oct 19, 2026$27.12$27.84$26.525$27.621.38M
Oct 16, 2026$27.42$27.42$26.275$26.731.46M
Oct 15, 2026$28.03$28.33$27.475$27.511.65M
Oct 14, 2026$28.46$28.79$27.83$27.901.77M
Oct 13, 2026$29.37$29.64$28.70$28.711.25M
Oct 12, 2026$30.17$30.595$28.61$29.482.24M
Oct 9, 2026$30.25$30.64$30.065$30.471.49M
Oct 8, 2026$31.40$31.50$29.80$30.261.76M
Oct 7, 2026$31.72$32.75$31.58$32.041.13M
Oct 6, 2026$33.51$33.51$31.36$32.111.67M
Oct 5, 2026$33.99$33.99$32.95$33.251.1M

Latest IMVT news

The latest Smart Investors Daily articles mentioning IMVT.

Stock researchCompany · Overview

IMVT research

Overview

Company profile and research snapshot.

Company profile

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$16.00
Implied upside
—
Analysts
—
IMVT recent ratings
DateFirmRatingTarget
Aug 4, 2026JP MorganOverweight—
Jun 30, 2026CitigroupBuy—
May 26, 2026GuggenheimBuy—
May 22, 2026Truist SecuritiesHold—
May 21, 2026B of A SecuritiesBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 21, 2026

Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026

DURHAM, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) today announced that it will report its financial results for the second fiscal quarter ended September 30, 2026 on Monday, November 9, 2026 before the market opens. Roivant Sciences Ltd. (Nasdaq: ROIV), Immunovant’s majority stockholder, will host a live conference call and webcast at 8:00 a.m. ET that same day, which will include a business update for Immunovant. To access the Roivant conference call by phone, plea

Yahoo · Oct 20, 2026

Immunovant (IMVT) Stock Looks Stretched On Book Value Alone

Immunovant has delivered a striking 5 year return, yet the recent pullback and legal questions around its governance put fresh focus on whether the current share price still lines up with what its balance sheet supports. For investors, the issue is whether the stock's recent history and headlines are outpacing the value implied by its book value. Over the past 5 years the stock has gained about 236.4%, which puts a lot of weight on whether its present valuation can still be grounded in the...

Benzinga · Oct 14, 2026

Immunovant Q1 2027 Earnings Call: Complete Transcript

Immunovant (NASDAQ:IMVT) held its first-quarter earnings conference call on Thursday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and financial

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By